Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab

• Váldodahkkit: Sandor Schokker (Dahkki), Fabrizia Fusetti (Dahkki), Francesco Bonardi (Dahkki), Remco J. Molenaar (Dahkki), Ron A.A. Mathôt (Dahkki), Hanneke W.M. van Laarhoven (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Given the increasing use of combination therapy with multiple monoclonal antibodies (mAbs), there is a clinical need for multiplexing assays. For the frequently co-administered anti-human epidermal growth factor receptor 2 (HER2) mAbs trastuzumab and pertuzumab, we developed a high-throughput and ro...